There are 717 resources available
377O - A randomized double-blind phase III study of niraparib versus placebo as maintenance therapy in extensive-stage small cell lung cancer
Presenter: Xinghao Ai
Session: Proffered paper session on Thoracic cancers
Resources:
Abstract
Slides
Webcast
199O - A phase II study investigating neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive bladder cancer: Final analysis
Presenter: Bernadett Szabados
Session: Proffered paper session on Genitourinary tumours
Resources:
Abstract
Slides
Webcast
200O - Pembrolizumab plus axitinib (pembro + axi) vs sunitinib in metastatic renal cell carcinoma (mRCC) outcomes of the KEYNOTE-426 study in patients from eastern Asia
Presenter: Chihiro Kondoh
Session: Proffered paper session on Genitourinary tumours
Resources:
Abstract
Slides
Webcast
217O - Pembrolizumab (pembro) combination therapies in patients with metastatic castration-resistant prostate cancer (mCRPC): Cohorts A-C of the phase Ib/II KEYNOTE-365 study
Presenter: Anthony M. Joshua
Session: Proffered paper session on Genitourinary tumours
Resources:
Abstract
Slides
Webcast
114O - Assessment of robotic versus laparoscopic distal gastrectomy for gastric cancer: A randomized controlled trial
Presenter: Jun Lu
Session: Proffered paper session on Gastrointestinal tumours
Resources:
Abstract
79O - Clinical performance of Immunoscore® in early colon cancer in the Asian population
Presenter: Jerome Galon
Session: Proffered paper session on Gastrointestinal tumours
Resources:
Abstract
Slides
Webcast
318O - Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients
Presenter: David Pinato
Session: Proffered paper session on SARS and Covid19
Resources:
Abstract
Slides
Webcast
319O - The systemic pro-inflammatory response identifies cancer patients with adverse outcomes from SARS-CoV-2 infection
Presenter: Gino Dettorre
Session: Proffered paper session on SARS and Covid19
Resources:
Abstract
Slides
Webcast
LBA4 - GEMSTONE-302: A phase III study of platinum-based chemotherapy (chemo) with placebo or CS1001, an anti-PDL1 antibody, for first-line (1L) advanced non-small cell lung cancer (NSCLC)
Presenter: Caicun Zhou
Session: Proffered paper session on Thoracic cancers
Resources:
Abstract
Slides
Webcast
LBA2 - Sintilimab plus bevacizumab biosimilar vs sorafenib as first-line treatment for advanced hepatocellular carcinoma (ORIENT-32)2
Presenter: Zhenggang Ren
Session: Proffered paper session on Gastrointestinal tumours
Resources:
Abstract
Slides
Webcast